← boardnext 2026-12
BRTX
BioRestorative Therapiesdistress 9/10 · high distress / dilution risk$0.34+6%today-82% from 52w high
Lead: chronic lumbar disc disease
Revenue
pre-revenue
Liquidity
$4M
Runway
0.3 yrs
Shares 1y
+219%
Price & events
-71.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+5.7%
1D
-4.5%
1W
-12.6%
1M
+50.4%
3M
-70.6%
6M
-80.3%
1Y
-80.4%
2Y
-98.3%
5Y
-98.9%
All
Overview
- Market Cap
- $8.54M
- Volume
- 57.76K
- 52 Week Range
- $0.17 – $1.84
- Total Shares
- 25.48M
- Float Shares
- 24.18M
- Short %
- 4.40%
- % Held by Insiders
- 12.13%
- % Held by Institutions
- 7.26%
- RVOL
- 0.13x
- Beta
- 0.64
Pipeline stages · 1 programs
BRTX-100
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | BRTX-100fast track | Lumbar Disc Disease | — | recruiting |
Catalyst news & presentations · 3
- February 8, 2025conferencedata presentationsecondaryPresented at Orthopaedic Research Society (ORS) 2025 Annual MeetingSEC 8-K
- before the end of 2024enrollment completesecondaryPhase 2BRTX-100 · target to complete patient enrollment in Phase 2 BRTX-100 studySEC 8-K
- November 13, 2024conferencedata presentationsecondaryPhase 2BRTX-100 · Presentation of additional preliminary 26-52 week blinded data from ongoing Phase 2 trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-08-14Roth MKMBuy
Competitors — chronic lumbar disc disease
- none identified
Recent news
- 2026-07-17BioRestorative Therapies Overhauls Leadership and Board Governance - TipRanks
- 2026-07-16BioRestorative Therapies, Inc. Announces CFO Changes, Effective July 13, 2026 - marketscreener.com
- 2026-06-28Price to earnings forward of BioRestorative Therapies, Inc. – NASDAQ:BRTX - TradingView
- 2026-06-27BioRestorative (NASDAQ:BRTX) Gains Penny Stock Attention - Kalkine Media
- 2026-06-26BioRestorative Therapies, Inc. Actuals & Estimates (NASDAQ:BRTX) - TradingView
- 2026-06-26BRTX Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-25BioRestorative finishes BRTX-100 Phase 2 supply in-house - Stock Titan
- 2026-06-25BioRestorative Therapies Announces Completion of BRTX-100 - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.